title: CTC-11 (Teijin).
abstract: Teijin and Chemo-Sero are codeveloping CTC-111 as a treatment for disseminated intravascular coagulation (DIC) due to protein C deficiency. The drug was launched for the treatment of protein C deficiency in Japan on January 31, 2001 and as of October 2001 was awaiting approval for the treatment of DIC, also in Japan [426762]. CTC-111 was evaluated in a multicenter pharmacokinetic trial in venous thrombosis patients with inherited protein C deficiency. CTC-111 was effective in six of ten patients with venous thrombosis, six of seven patients with deep vein thrombosis and two of three patients with pulmonary embolism. Treatment was safe and effective and there were no serious adverse events [350149].
authors.affiliation: Division of Pharmacology, Department of Medicine and Care, Faculty of Health Sciences, Linköpings Universitet, SE-581 85, Linköping, Sweden. Per.Whiss@hul.liu.se
authors.forename: P A
authors.initials: PA
authors.lastname: Whiss